Robert Izquierdo, The Motley Fool
4 min read
Vikram Verghese, Chief Financial Officer of HeartFlow, Inc. (NASDAQ:HTFL), sold 33,416 shares in trades executed on September 2, 2026 and September 3, 2026. SEC Form 4 filing
Transaction summary
Transaction value based on SEC Form 4 weighted average sale price ($49.85); post-transaction value based on September 3, 2026 market close ($49.71).
Key questions
-
What prompted this disposition of common stock?
The trades were conducted according to a pre-arranged Rule 10b5-1 trading plan established on June 4, 2026, which allows corporate insiders to sell a predetermined number of shares at set times to avoid concerns regarding material non-public information. -
What is the executive’s remaining equity position in the company?
Following the disclosed sale, Vikram Verghese maintains a direct ownership interest of 221,143 shares, which represents an approximate 0.26% stake in the San Francisco-based medical technology company. -
How has the stock performed relative to this liquidity event?
The company’s stock returned 59% in the 12 months ending September 3, 2026, and was priced at $48.91 as of the September 4, 2026 market close.
Company Overview
Company Snapshot
-
HeartFlow provides a proprietary artificial intelligence-powered platform that generates three-dimensional digital replicas of patients’ hearts from coronary computed tomography angiography scans, enabling non-surgical diagnosis and management of coronary artery disease.
-
The company generates revenue through licensing its HeartFlow Platform to healthcare providers and institutions, which utilize the technology to improve diagnostic accuracy and clinical decision-making for cardiac patients.
-
HeartFlow’s primary customers include hospitals, imaging centers, and cardiology practices globally that seek advanced diagnostic solutions to reduce unnecessary invasive procedures and improve patient outcomes in coronary artery disease management.
HeartFlow operates as a global medical technology company headquartered in San Francisco. The company has demonstrated significant market momentum, with its stock appreciating 58.92% over the past twelve months, reflecting investor confidence in its innovative cardiac diagnostic platform.
Despite current trailing 12-month net losses of $118.4 million, HeartFlow’s competitive positioning in the high-growth cardiac imaging and artificial intelligence sectors positions it as a transformative player in non-invasive coronary artery disease diagnosis.
